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What’s Known on This Subject
ICH is the most devastating complication of ECMO. There is a continuous search for risk
or predicting factors. There are no previous data about volume administration and ICH
during ECMO.
What This Study Adds
To our knowledge, this is the ﬁrst study to ﬁnd a statistically signiﬁcant relationship
between intravascular volume administration and the occurrence of ICH during ECMO.
ABSTRACT
OBJECTIVE. The objective of this study was to determine the relationship between the
frequency and total volume of intravascular volume administration and the devel-
opment of intracranial hemorrhage during venoarterial extracorporeal membrane
oxygenation.
METHODS. In a retrospective, matched, case-control study, 24 newborns who developed
an intracranial hemorrhage during venoarterial extracorporeal membrane oxygen-
ation treatment were compared with 40 control subjects. Both groups were analyzed
for gestational age, gender, race, Apgar scores at 1 and 5 minutes, birth weight,
cardiopulmonary resuscitation before venoarterial extracorporeal membrane oxy-
genation, age at the start of treatment, duration of treatment, worst arterial blood gas
sample preceding treatment, activated clotting time values, need for platelet trans-
fusions, mean blood pressure, and the use of inotropics and steroids before the
treatment. For both groups, total number and volume of intravascular infusions of
normal saline, pasteurized plasma protein solution, erythrocytes, and platelets dur-
ing the first 24 hours of treatment were determined. Variables were analyzed in their
relationship to intracranial hemorrhage by using univariate and multivariate condi-
tional logistic regression.
RESULTS. The only statistically significant difference in patient characteristics between
the case patients and control subjects was arterial blood gas values. Newborns who
developed intracranial hemorrhage during the treatment received both a statistically
significantly higher number and a statistically significantly higher total volume of
intravascular volume administrations compared with control patients. After adjust-
ment for pH, PaCO2, and PaO2 in the multivariate analysis, we found a significant
relation between the development of intracranial hemorrhage and 8 infusions or
300 mL of volume infusion in the first 8 hours and 10 infusions in the first 24 hours of treatment.
CONCLUSIONS. The number and total volume of intravascular volume administration in the first 8 and 24 hours of
venoarterial extracorporeal membrane oxygenation treatment are statistically significantly related to the develop-
ment of intracranial hemorrhage. Pediatrics 2008;121:e1599–e1603
SINCE BARTLETT AND colleagues in 1976 treated the first newborn successfully with venoarterial extracorporealmembrane oxygenation (va-ECMO),1 ECMO has become a rescue therapy for neonates with severe but
potentially reversible respiratory failure when maximal conventional therapy has failed. Without ECMO, the
mortality rate is high.2,3 More than 22 000 neonates have been treated with ECMO, 15 000 of whom were treated
with va-ECMO, with an overall survival rate of 80%.4 Although ECMO has increased survival, the occurrence of
hemorrhagic and ischemic cerebral lesions, resulting in future neurologic and neurodevelopmental dysfunction, are
major complications.5,6 Imaging studies revealed intracranial hemorrhage (ICH) or ischemic abnormalities in 10 up
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determined by pre-ECMO– as well as ECMO-related
events or conditions.10 Optimizing neurologic outcome
remains 1 of the priorities in ECMO research. The pop-
ulation at greatest risk for ICH, however, is not clearly
defined. Hardart et al11,12 determined gestational age,
postconceptional age, acidosis, sepsis, coagulopathy, and
treatment with epinephrine as independent factors as-
sociated with ICH in neonates who were treated with
ECMO. A study by Dela Cruz et al13 demonstrated that
an elevated activated clotting time (ACT) and low plate-
let counts that required transfusion were statistically
associated with an increase in the development of ICH.
Hirthler et al14 reviewed that instability of ACT and
platelet count are early predictors of ICH. Finally, lactate
before ECMO treatment was found to be a useful marker
for the development of ICH during ECMO.15
Especially during the first days of ECMO, intravascu-
lar volume administration is regularly required. One
reason is the occurrence of bladderbox alarms, as a sign
of inadequate venous drainage from the right atrium to
maintain the required flow of the ECMO system, which
is aimed to realize adequate oxygenation of the patient.
In a reaction, volume administration is often given when
other causes of bladderbox alarms are ruled out. Next to
this anemia or thrombocytopenia are reasons to add
volume with blood products. From our clinical experi-
ence, we had the impression that neonates who required
frequent volume administration during the first days of
the va-ECMO treatment developed ICH more fre-
quently. The objective of this study was to investigate
whether there is a relationship between intravascular
volume administration and the occurrence of ICH in the
neonate during treatment with va-ECMO.
METHODS
From September 1989 through November 2005, 236 new-
borns (64% boys, 36% girls) were treated with va-ECMO
at the Radboud University Nijmegen Medical Centre.
Overall survival rate was 77%, and ICH occurred in 25
(11%) patients. All patients with ICH were analyzed to
participate in a matched case-control study. One patient
was excluded because of congenital abnormality of the
heart, so 24 patients with ICH were included in the study.
ICHwas diagnosed by cerebral ultrasound, performed daily
during the ECMO treatment (n[r]  18), by computed
tomography (CT), or by MRI in the period directly after
decannulation (n  6). The 24 newborns who developed
an ICH related to va-ECMO treatment (case patients) were
matched with 40 patients who did not develop ICH (con-
trol subjects). Each pair of 1 case patient and 1 or 2 control
subjects was matched for diagnosis, gestational age (1
week), and birth weight (500 g). For statistical reasons,
we aimed for 2 control subjects for each case patient.When
2 possible candidates were available, the patients whose
dates of birth were closest to that of the case patient were
selected as control subjects. Newborns were excluded
from the study when there were congenital abnormalities
other than congenital diaphragmatic hernia; a second
ECMO treatment, ICH before the initiation of ECMO; or
coagulation disorders as screened for by the determination
of prothrombin time, activated partial thromboplastin
time, and platelet count. Cerebral ultrasound, none of
them showing ICH, was performed for all patients, case
patients and control subjects, before the ECMO treatment.
Before the initiation of ECMO, informed consent from the
parents was obtained, and all case patients and control
subjects met institutional criteria for ECMO treatment,
which did not change during the study period. All patients
were treated with va-ECMO. The ECMO circuit itself con-
sisted of a custom-packed 1⁄4-in flexible polyvinylchloride
tubing (Baxter, Uden, Netherlands) with a silicone reser-
voir, the bladderbox (Seabrook Medical System, Værløse,
Denmark), a 0.6-m2 membrane oxygenator (Scimed Life
Systems, Minneapolis, MN), a heat exchanger (Cincinnati
Sub Zero, Cincinnati, OH), and a roller pump (Polystan
A/S, Copenhagen, Denmark).
A loading dose of heparin was given before cannulation
to achieve an ACT of300 seconds. After this, hepariniza-
tion was checked every hour by measurement of the ACT
aiming for values between 200 and 220 seconds (Hemo-
chron). During the course of ECMO, platelet transfusions
were given to maintain a platelet count 80 000/mm3.
Erythrocyte transfusions were given to maintain a hemo-
globin level 8.0 mmol/L and a hematocrit value 0.40
L/L. Hemoglobin level and platelet count were determined
every 4 hours. Normal saline (NaCl 0.9%) and pasteurized
plasma protein solution (albumin 3.8%) were used to re-
store the ECMO flow after bladderbox alarms caused by
insufficient blood drainage from the right atrium.
Cerebral ultrasound imaging through the anterior
fontanel (Philips HDI-3000, Ultrasound, Inc, Bothell,
WA) was performed daily to check for ICH. Images were
interpreted by the neonatologist and the pediatric neu-
rologist. After decannulation, CT or MRI was performed
on all patients and analyzed by the neuroradiologists.
To check the matching procedure and possible differ-
ences between the case patients and the control subjects,
both groups were analyzed for gestational age, gender,
race, Apgar scores at 1 and 5 minutes, birth weight, car-
diopulmonary resuscitation (CPR) before ECMO, age at the
start of ECMO, duration of ECMO treatment, survival,
worst arterial blood gas sample in the 6 hours preceding
ECMO, number and volume of required thrombocyte
transfusions, ACT value after the loading dose at the start of
ECMO, mean of ACT and mean blood pressure values as
well as the coefficient of variation for ACT andmean blood
pressure during the first 8 and 24 hours of ECMO, and the
use of inotropics (dopamine, dobutamine, epinephrine,
norepinephrine) and steroids before the start of ECMO.
To investigate the relationship between intravascular
volume administration and the occurrence of ICH, we
analyzed the number and volume of intravascular infu-
sions of normal saline, pasteurized plasma protein solu-
tion, erythrocytes, and platelets during the first 8 and 24
hours of ECMO treatment. Data were collected from the
international Extracorporeal Life Support Organization
forms, patient files, and patient medical checklists in
which physiologic parameters, laboratory results, and
ACT values were written down every hour and all vol-
ume administrations are registered.
Statistical analysis was performed by using SPSS 13.0
(SPSS Inc, Chicago, IL). Patient characteristics were an-
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alyzed by Student’s t tests for comparison of means (P 
.05) and 2 tests (P  .05) for dichotomized character-
istics. Univariate and multivariate testing of variables in
their relation to ICH was performed by use of conditional
logistic regression. For several variables, the cutoff points
for which dichotomization of the variable leads to a
statistically significant odds ratio (OR) at univariate anal-
ysis were determined by stepwise changing the segrega-
tion value for dichotomization. Steps were 0.1 for pH, 5
mm Hg for PaCO2 and PaO2, 100 mL for the volume of
infusions, and 1 for the number of infusions. Variables
that were found to have a significant relationship with
the development of ICH in the univariate analysis were
further used in the multivariate conditional logistic re-
gression. ORs and 95% confidence intervals (CIs) were
determined. Because CPR, gestational age, and age at the
start of ECMO are generally considered to be important
in their relation to ICH, we performed a univariate as
well as a multivariate analysis for these terms. In the
latter, the outcome for volume administration was cor-
rected for each separate parameter, CPR, gestational age,
and age at the start of ECMO.
RESULTS
All 24 newborns who developed an ICH during va-
ECMO treatment could be matched with 1 or 2 control
patients with the same primary diagnosis. Primary diag-
noses for the case patients in this study were as follows:
congenital diaphragmatic hernia in 8 (33%), sepsis in 8
(33%), meconium aspiration syndrome in 5 (21%), and
primary pulmonary hypertension in 3 (13%). The other
matching parameters used (gestational age and birth
weight) were not significantly different between the case
patients and control subjects (Table 1). Maximum time
span between a case patient and his or her control sub-
ject(s) was 8 months. In this study, we found the fol-
lowing types of ICH: parenchymal in 10 (42%), intra-
ventricular in 9 (38%), subependymal in 3 (13%),
petechial in 1 (4%), and in the posterior fossa in 1 (4%).
Of these 24 cases of ICH, 18 were diagnosed by cerebral
ultrasound during va-ECMO and 6 were diagnosed by
either CT or MRI after decannulation. Of the 18 cases of
ICH on cerebral ultrasound, 8 (44%) were demonstrated
within 24 hours after the start of va-ECMO and 14
(78%) within 72 hours. Also, for other than the match-
ing variables, we found no statistically significant differ-
ences in patient characteristics, except for pH and sur-
vival (Table 1). Next to these characteristics, we found
no significant differences in ACT values, platelet require-
ment, blood pressures, the use of inotropics and steroids,
or race of the patients.
At dichotomization, we found the following statisti-
cally significant values in the univariate conditional lo-
gistic regression for the worst arterial blood gas samples
in the 6 hours preceding the ECMO treatment in relation
to the development of ICH: pH7.3, PaCO245 mm Hg,
and PaO2 50 mm Hg (Table 2). These parameters were
further used in the multivariate conditional logistic re-
gression.
Single infusions of intravascular volume administra-
tion ranged from 20 to 50 mL. In Fig 1, it is shown that
the newborns who developed ICH during the treatment
with va-ECMO had received both a statistically signifi-
cantly higher number and a statistically significantly
TABLE 1 Patient Characteristics of Newborns With ICH (Case







Mean SD Mean SD
Birth weight, kg 3.3 0.5 3.3 0.5 .79
Gestational age, wk 38 3 39 2 .64
Age at start of ECMO, h 35 30 53 64 .20
Duration of ECMO, h 155 76 171 81 .43
Apgar at 1 min, median 6.0 2.6 6.1 2.5 .94
Apgar at 5 min, median 7.0 2.0 7.1 2.1 .82
pH 7.23 0.15 7.33 0.15 .01
PaCO2, mmHg 45.8 13.9 42.7 16.7 .46
PaO2, mmHg 48.1 29.6 53.7 19.1 .36
Gender, male/female 17/7 28/12 — — 0.93
CPR before ECMO 3/24 3/40 — — 0.51
Survival 11/24 32/40 — — 0.01
No. of platelet T24 2.1 1.2 1.6 1.2 .64
Volume of platelet T24, mL 85 48 67 48 .18
Loading ACT 399 136 397 161 .96
ACT, ﬁrst 8 h 276 35 266 54 .42
ACT, ﬁrst 24 h 258 34 246 34 .19
CV ACT, ﬁrst 8 h 0.17 0.09 0.15 0.09 .41
CV ACT, ﬁrst 24 h 0.15 0.07 0.15 0.10 .75
Mean MAP, ﬁrst 8 h 53 10 56 7 .24
Mean MAP, ﬁrst 24 h 52 8 53 7 .63
CV MAP, ﬁrst 8 h 0.13 0.06 0.14 0.06 .60
CV MAP, ﬁrst 24 h 0.13 0.07 0.15 0.06 0.42
Use of steroids 3/24 5/40 — — 0.82
Use of inotropics 21/24 38/40 — — 0.31
Number and volume of platelet T24 number and total volumes (mL) of platelet transfusions
to keep platelet counts at80 000/mm3 in the ﬁrst 24 hours of ECMO. Inotropics used were
dopamine, dobutamine, epinephrine, and norepinephrine. CV indicates coefﬁcient of variation;
MAP, mean arterial blood pressure.
TABLE 2 ORs and CIs for the Relation Between pH, PaCO2, PaO2, and
the Number and Total Volume of Intravascular Infusion in









pH7.3 worst arterial gas 4.5 (1.4–14.0) — —
PaCO245 mmHg worst arterial gas 3.3 (1.0–10.9) — —
PaO250 mmHg worst arterial gas 5.3 (1.5–19.0) — —
Every 100 mL of volume, ﬁrst 8 h 1.5 (1.1–2.2) 1.6 (1.0–2.6) .06
300 mL, ﬁrst 8 h 6.3 (1.4–29.1) 10.0 (1.9–83.5) .03
Every single infusion, ﬁrst 8 h 1.2 (1.0–1.5) 1.3 (1.0–1.6) .04
8 infusions, ﬁrst 8 h 13.6 (1.7–106.3) 26.0 (1.6–430.2) .02
Every 100 mL of volume, ﬁrst 24 h 1.4 (1.1–1.8) 1.6 (1.0–2.4) .04
400 mL, ﬁrst 24 h 5.7 (1.3–25.6) 6.4 (0.5–77.1) NS
Every single infusion, ﬁrst 24 h 1.1 (1.0–1.3) 1.2 (1.0–1.4) .04
10 infusions, ﬁrst 24 h 3.6 (1.1–11.2) 8.5 (1.2–59.2) .03
Results are given for the univariate analysis and the multivariate analysis (adjustment for pH,
PaCO2, and PaO2 mentioned) for the ﬁrst 8 and 24 hours of the treatment with va-ECMO. NS
indicates not statistically signiﬁcant.
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higher total volume of intravascular volume administra-
tions during the first 8 and 24 hours of the treatment
with va-ECMO, compared with the matched control
patients. Statistically, there was a significant increase in
the risk for ICH for every extra infusion in the first 8 and
24 hours of treatment with va-ECMO. This was also true
for every 100 mL of extra volume administration in the
first 8 and 24 hours (Table 2). After dichotomization and
adjustment for pH, PaCO2, and PaO2 in the multivariate
conditional regression, we found the following condi-
tions to be significantly related to the development of
ICH during the va-ECMO treatment: 8 infusions or
300 mL of intravascular infusion in the first 8 hours of
va-ECMO and 10 infusions in the first 24 hours of
va-ECMO. An overview of ORs and 95% CIs for the
univariate and multivariate analysis is shown in Table 2.
In the univariate analysis, CPR, gestational age, and
age at the start of ECMO did not seem to be significant
risk factors for the development of ICH. ORs and CIs
were 2.0 (0.4–9.0), 0.4 (0.1–1.4), and 1.0 (0.9–1.0),
respectively. When these terms were used in a straight
multivariate conditional regression, data found for vol-
ume administration, as shown in Table 2, were still
statistically significant.
DISCUSSION
Because ICH is one of the most devastating complica-
tions of ECMO, it is of ongoing importance to identify
patients who are most at risk and eliminate risk factors as
much as possible. This matched case-control study is the
first to describe a statistically significant relationship be-
tween the total number and volume of intravascular
volume infusions and the development of ICH during
the treatment with va-ECMO. We found that neonates
who received 8 infusions or 300 mL of volume in-
fusion during the first 8 hours or 10 infusions during
the first 24 hours of va-ECMO were statistically signifi-
cant more at risk to develop an ICH. We stress that this
relationship does not have to be necessarily causal. A
hypothetical explanation, however, might be found in
disturbances of cerebral hemodynamics caused by the
infusions of intravascular volume administration and/or
the often preceding bladderbox alarms with consecutive
acute interruption of the roller pump resulting in inter-
ruption of blood flow to the patient. In normal, healthy
situations, cerebral autoregulation maintains the cere-
bral blood flow over a wide range of cerebral perfusion
pressures with a contraregulation response occurring
with a delay of 2 seconds after sudden changes in blood
pressure. It has been shown, however, that autoregula-
tion is disturbed in severely ill term infants.16–19 Addi-
tionally studies of newborn lambs showed that pro-
longed hypoxia and/or the ECMO treatment itself will
significantly disturb the autoregulation20–23; therefore,
frequent interruption of the roller pump, followed by
infusion of intravascular volume administration, may
result in frequent fluctuations in cerebral blood flow, a
known risk factor for ICH. Besides this, possible distur-
bances in cerebral blood flow at bladderbox alarms
might be too acute to be compensated for by the auto-
regulation system, even if not disturbed. The combina-
tion of most bladderbox alarms and intravascular vol-
ume infusion in the first 24 hours and disturbed
autoregulation may be a part of the explanation of why
most ICHs occur in the first few days of the ECMO
treatment; however, another explanation of the rela-
tionship found in this study might be that the pathologic
process that leads to ICH also causes the inadequate
venous drainage to the ECMO circuit, which in turn
leads to the need for volume administration.
Birth weight and gestational age were not signifi-
cantly different between the ICH group and the group
without ICH, which suggests that the matching proce-
dure was successfully performed. The significant rela-
tionship between pH, PaCO2, and PaO2 and ICH found in
this study confirms the findings of previous studies.12,13,15
Confirmation of acidosis by using lactate as other vari-
able was not possible, because this was not always rou-
tinely determined.
In contradiction to the study of Dela Cruz et al,13 ACT
levels, analyzed for the first 8 and 24 hours between case
patients and control subjects, were not significantly dif-
ferent. Instability of ACT during the ECMO treatment
was described by Hirthler et al14 but not further con-
firmed in this study, neither by the mean ACT nor by the
coefficient of variation of the ACT. Because the exact
time of ICH occurrence is not known, instability of ACT
could be a risk factor as well as a consequence of the ICH.
This could also be the question for possible differences in
platelet counts. In all our patients, case patients and
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ICH (n = 24) 
Non-ICH (n = 40) 
FIGURE 1
Total number and volume of intravascular volume infusions
in the ﬁrst 8 and 24 hours between patients with and with-
out ICH during the treatment with ECMO. a P .03; b P
.005; c P .04.
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control subjects, platelet counts were kept strictly above
80 000/mm3. Platelet requirement was slightly higher in
the group of patients who developed an ICH, which
seems to fit with the previous studies described. In our
study, however, this was not statistically significant. We
did not find a statistically significant difference in the use
of epinephrine, as was found in the study by Hardart et
al,12 or in the use of other inotropic medication or ste-
roids before the ECMO treatment used to treat hypoten-
sion.
Although any confounding factor is not completely
excluded, we think that this matched case-control study
shows an important relationship between intravascular
volume administration and the development of ICH. The
results of this study can be translated to clinical practice.
Any newborn who is treated with va-ECMO and re-
quires high amounts or number of intravascular volume
administration should alert the ECMO team. Because of
the increased chance of ICH, more frequent neurologic
assessment and cerebral ultrasounds are recommended
to detect any ICH in an early stage and if possible avoid
extension of the hemorrhage.
Additional prospective studies, as currently initiated
in our ECMO center, are required to analyze the mech-
anisms by which volume administration and/or the of-
ten preceding bladderbox alarms are related to the de-
velopment of ICH. Knowledge of these mechanisms may
be useful for the development of strategies to reduce the
risk for ICH during the va-ECMO treatment, such as
how to react on bladderbox alarms and whether it might
be indicated to be cautious with intravascular volume
administration.
CONCLUSIONS
To our knowledge, this is the first study to show a
statistically significant relationship between the total
amount and number of intravascular volume adminis-
tration and the development of ICH during va-ECMO
treatment. Additional studies are needed to investigate
the pathophysiologic mechanisms of this relationship.
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